Not applicableStudy completedNCT00900302What this trial is testingOX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With CancerWho this might be right forCancer OHSU Knight Cancer Institute 98
Early research (Phase 1)Study completedNCT00004074What this trial is testingInterleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuWho this might be right forAdvanced Adult Primary Liver CancerAnaplastic Thyroid CancerBone Metastases+124 more National Cancer Institute (NCI) 15
Early research (Phase 1)Looking for participantsNCT04704661What this trial is testingTesting the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialWho this might be right forAdvanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more National Cancer Institute (NCI) 51
Testing effectiveness (Phase 2)UnknownNCT00003251What this trial is testingAmifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck CancerWho this might be right forDrug/Agent Toxicity by Tissue/OrganHead and Neck CancerRadiation Toxicity University of Illinois at Chicago 46
Testing effectiveness (Phase 2)Study completedNCT00021047What this trial is testingEpirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid TumorWho this might be right forEsophageal CancerExtrahepatic Bile Duct CancerGastric Cancer+3 more National Institutes of Health Clinical Center (CC)
Early research (Phase 1)Study completedNCT00031681What this trial is testing7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)Who this might be right forAdvanced Adult Primary Liver CancerCarcinoma of the AppendixEstrogen Receptor-negative Breast Cancer+85 more National Cancer Institute (NCI) 41
Early research (Phase 1)Study completedNCT00028496What this trial is testingVaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerWho this might be right forAdenocarcinoma of the ColonAdenocarcinoma of the GallbladderAdenocarcinoma of the Pancreas+39 more National Cancer Institute (NCI) 48
Early research (Phase 1)Study completedNCT00004178What this trial is testingGene Therapy in Treating Patients With CancerWho this might be right forCancer Roger Williams Medical Center
Early research (Phase 1)Study completedNCT00020579What this trial is testingMS-275 in Treating Patients With Advanced Solid Tumors or LymphomaWho this might be right forCancer National Institutes of Health Clinical Center (CC) 75
Very early researchEnded earlyNCT00499733What this trial is testingCyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial CancerWho this might be right forCancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Large-scale testing (Phase 3)Study completedNCT00538850What this trial is testingFentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainWho this might be right forCancer INSYS Therapeutics Inc 130
Early research (Phase 1)Study completedNCT00049296What this trial is testingThalidomide and Docetaxel in Treating Patients With Advanced CancerWho this might be right forCancer Case Comprehensive Cancer Center 26
Testing effectiveness (Phase 2)Study completedNCT00101348What this trial is testingErlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerWho this might be right forMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Basal Cell Carcinoma of the Lip+64 more National Cancer Institute (NCI) 66
Not applicableLooking for participantsNCT01365169What this trial is testingAssociation Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"Who this might be right forMalignant Head and Neck NeoplasmMalignant NeoplasmMetastatic Malignant Neoplasm in the Neck+45 more M.D. Anderson Cancer Center 590
Early research (Phase 1)Study completedNCT02158234What this trial is testingStereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and NeckWho this might be right forSquamous Cell Carcinoma of the Head and Neck H. Lee Moffitt Cancer Center and Research Institute 20
Early research (Phase 1)Study completedNCT00005842What this trial is testingTrastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerWho this might be right forCancer National Cancer Institute (NCI) 24
Early research (Phase 1)Study completedNCT00010023What this trial is testingCapecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid TumorsWho this might be right forCancer NYU Langone Health
Testing effectiveness (Phase 2)Looking for participantsNCT05408845What this trial is testingTesting the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersWho this might be right forMetastatic Salivary Gland CarcinomaRecurrent Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8+2 more NRG Oncology 146
Early research (Phase 1)Study completedNCT00101972What this trial is testingRAV12 in Treating Patients With Metastatic or Recurrent AdenocarcinomaWho this might be right forCancer MacroGenics 53
Early research (Phase 1)Active Not RecruitingNCT04576091What this trial is testingTesting the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerWho this might be right forClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck+29 more National Cancer Institute (NCI)